00059-7/asset/4cbe94fb-e0c0-468a-b4fb-2f4f4b6116b9/main.assets/gr3a_lrg.jpg)
HealthMore in Health→
RIO Trial Finds Broadly Neutralizing Antibodies Delay HIV Viral Rebound After Treatment Interruption
Key Takeaways
- The phase II randomized controlled RIO trial reported secondary and exploratory outcomes in adult males living with HIV who underwent analytical treatment interruption.
- Published findings describe delayed viral rebound among participants receiving broadly neutralizing antibody-based intervention.
- The trial also documented resistance to broadly neutralizing antibodies, with 3BNC117 named in the reported results.
- Results were published in Nature Medicine on 15 September 2026.
DE
DT Editorial Team··via nature.com